A high-level overview of Ligand Pharmaceuticals Incorporated (LGND) stock. View (LGND) real-time stock price, chart, news, analysis, analyst reviews and more.

At Ligand Pharmaceuticals Inc (NASD: LGND), 3 different insiders purchased 855 shares at an average price of $43.79/share, for a total [...] By Dividend Channel Contributor Nov 22, 2013 ...

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025. JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ...

A Look at Receptor–Ligand Pairs for Active-Targeting Drug Delivery from Crystallographic and Molecular Dynamics Perspectives. Gergana Gocheva. Gergana Gocheva. Sofia University “St. Kliment Ohridski”, ...

Ligand L5 has Brønsted basicity very similar to that of L4, ... The Pd(II) complexes of the ambidentate pyridyldiketones 2,2-dimethyl-5-(3- or 4-pyridyl)pentane-3,5-dione are readily prepd. in their ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

LOS ANGELES, June 03, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO ...

A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).

Delta-like ligand 3 (DLL3), a Notch signaling regulator overexpressed in 70–80% of SCLC tumors, has emerged as a simultaneous biomarker and therapeutic target. This review aims to synthesize recent ...